# Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

> **NCT00792506** · PHASE2 · TERMINATED · sponsor: **Italfarmaco** · enrollment: 1 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ITF2357

## Key facts

- **NCT ID:** NCT00792506
- **Lead sponsor:** Italfarmaco
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was prematurely discontinued for lack of recruitement.
- **Last updated:** 2022-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00792506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00792506, "Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00792506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*